Safety and Efficacy of Topical Simvastatin Plus Cholesterol Cream vs Topical Simvastatin Cream Alone for Porokeratosis Ptychotropica: A randomized, single-blind, split-body, placebo-controlled investigator-initiated trial

Supplementary Fig 1. The genotype and phenotype of the 18 enrolled patients.
Supplementary Fig 2. The clinical responses of porokeratosis ptychotropica patients after topical simvastatin treatment.
Supplementary Fig 3. The improvement ratio of porokeratosis ptychotropica patients from the 2% simvastatin and the 2% simvastatin/2% cholesterol group at preliminary assessment (week 8).
Supplementary Fig 4. Analysis of the PPASI score decline from baseline to week 48 of porokeratosis ptychotropica patients between the 2% simvastatin and the 2% simvastatin/2% cholesterol group.
Supplementary Fig 5. The responses of erythema, thickness, and scaling after topical simvastatin treatment.
Supplementary Table I. The PPASI score about the degree of redness (erythema, E), thickness (induration, I), and scaling (desquamation, D) of the lesions.
Supplementary Table II. The score of the affected area was assigned with the percentage of affected body surface area (BSA) on the buttocks.

补充图1. 18例入组患者的基因型与表型。
补充图2. 铺褶状汗孔角化病（porokeratosis ptychotropica）患者外用辛伐他汀治疗后的临床应答情况。
补充图3. 2%辛伐他汀组与2%辛伐他汀/2%胆固醇组铺褶状汗孔角化病患者在初步评估（第8周）时的皮损改善率。
补充图4. 2%辛伐他汀组与2%辛伐他汀/2%胆固醇组铺褶状汗孔角化病患者从基线至第48周的PPASI评分降幅分析。
补充图5. 外用辛伐他汀治疗后红斑、皮损厚度及鳞屑的改善情况。
补充表1. 皮损红度（红斑，E）、厚度（浸润，I）及鳞屑（脱屑，D）程度对应的PPASI评分（Porokeratosis Area and Severity Index）。
补充表2. 以臀部体表面积（BSA，Body Surface Area）占比赋值的皮损受累面积评分。

搜集汇总

背景与挑战

背景概述

该数据集包含一项针对褶皱性角化病的临床试验结果，比较局部使用辛伐他汀联合胆固醇乳膏与单独使用辛伐他汀乳膏的安全性和有效性。数据集提供了补充图表和表格，详细记录了患者的临床反应、PPASI评分变化以及受影响区域评估，适用于分析局部治疗方法的疗效。